Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines

Authors: Stacey L Fossey, Misty D Bear, William C Kisseberth, Michael Pennell, Cheryl A London

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

We have previously demonstrated that both canine and human OSA cell lines, as well as 8 fresh canine OSA tumor samples, exhibit constitutive phosphorylation of STAT3, and that this correlates with enhanced expression of matrix metalloproteinase-2 (MMP2). While multiple signal transduction pathways can result in phosphorylation of STAT3, stimulation of the cytokine receptor gp130 through either IL-6 or Oncostatin M (OSM) is the most common mechanism through which STAT3 is activated. The purpose of this study was to evaluate the role of IL-6 and OSM stimulation on both canine and human OSA cell lines to begin to determine the role of these cytokines in the biology of OSA.

Methods

RT-PCR and Western blotting were used to interrogate the consequences of OSM and IL-6 stimulation of OSA cell lines. OSA cells were stimulated with OSM and/or hepatocyte growth factor (HGF) and the effects on MMP2 activity (gel zymography), proliferation (CyQUANT), invasion (Matrigel transwell assay), and VEGF production (Western blotting, ELISA) were assessed. The small molecule STAT3 inhibitor LLL3 was used to investigate the impact of STAT3 inhibition following OSM stimulation of OSA cells.

Results

Our data demonstrate that the OSM receptor (OSMR), but not IL-6 or its receptor, is expressed by all human and canine OSA cell lines and canine OSA tumor samples; additionally, OSM expression was noted in all tumor samples. Treatment of OSA cell lines with OSM induced phosphorylation of STAT3, Src, and JAK2. OSM stimulation also resulted in a dose dependent increase in MMP2 activity and VEGF expression that was markedly reduced following treatment with the small molecule STAT3 inhibitor LLL3. Lastly, OSM stimulation of OSA cell lines enhanced invasion through Matrigel, particularly in the presence of rhHGF. In contrast, both OSM and HGF stimulation of OSA cell lines did not alter their proliferative capacity.

Conclusions

These data indicate OSM stimulation of human and canine OSA cells induces STAT3 activation, thereby enhancing the expression/activation of MMP2 and VEGF, ultimately promoting invasive behavior and tumor angiogenesis. As such, OSM and its receptor may represent a novel target for therapeutic intervention in OSA.
Appendix
Available only for authorised users
Literature
1.
Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004, 9 (4): 422-441. 10.1634/theoncologist.9-4-422.CrossRefPubMed
2.
Withrow SJ, Powers BE, Straw RC, Wilkins RM: Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop. 1991, 270: 159-168.PubMed
3.
Ferracini R, Angelini P, Cagliero E, Linari A, Martano M, Wunder J, Buracco P: MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res. 2000, 18 (2): 253-256. 10.1002/jor.1100180213.CrossRefPubMed
4.
MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH, Radinsky R: c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003, 20 (5): 421-430. 10.1023/A:1025404603315.CrossRefPubMed
5.
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004, 10 (2): 182-186. 10.1038/nm982.CrossRefPubMed
6.
Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA: Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer. 2009, 9: 81-10.1186/1471-2407-9-81.CrossRefPubMedPubMedCentral
7.
Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P, Khanna C: Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics. 2009, 10: 625-10.1186/1471-2164-10-625.CrossRefPubMedPubMedCentral
8.
Chun R, de Lorimier LP: Update on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract. 2003, 33 (3): 491-516. 10.1016/S0195-5616(03)00021-4. viCrossRefPubMed
9.
Clark JC, Dass CR, Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008, 134 (3): 281-297. 10.1007/s00432-007-0330-x.CrossRefPubMed
10.
Bilbe G, Roberts E, Birch M, Evans DB: PCR phenotyping of cytokines, growth factors and their receptors and bone matrix proteins in human osteoblast-like cell lines. Bone. 1996, 19 (5): 437-445. 10.1016/S8756-3282(96)00254-2.CrossRefPubMed
11.
Tanaka M, Miyajima A: Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003, 149: 39-52. full_text.PubMed
12.
Brounais B, David E, Chipoy C, Trichet V, Ferre V, Charrier C, Duplomb L, Berreur M, Redini F, Heymann D, et al: Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone. 2009, 44 (5): 830-839. 10.1016/j.bone.2008.12.021.CrossRefPubMed
13.
Jorcyk CL, Holzer RG, Ryan RE: Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine. 2006, 33 (6): 323-336. 10.1016/j.cyto.2006.03.004.CrossRefPubMed
14.
Brounais B, Chipoy C, Mori K, Charrier C, Battaglia S, Pilet P, Richards CD, Heymann D, Redini F, Blanchard F: Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo. Clin Cancer Res. 2008, 14 (17): 5400-5409. 10.1158/1078-0432.CCR-07-4781.CrossRefPubMed
15.
Bishop KA, Meyer MB, Pike JW: A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. Mol Endocrinol. 2009, 23 (12): 2095-2110. 10.1210/me.2009-0209.CrossRefPubMedPubMedCentral
16.
Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem. 1996, 271 (51): 32635-32643. 10.1074/jbc.271.51.32635.CrossRefPubMed
17.
Kuropatwinski KK, De Imus C, Gearing D, Baumann H, Mosley B: Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. J Biol Chem. 1997, 272 (24): 15135-15144. 10.1074/jbc.272.24.15135.CrossRefPubMed
18.
Sims NA: gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice. Mol Cell Endocrinol. 2009, 310 (1-2): 30-39. 10.1016/j.mce.2008.08.025.CrossRefPubMed
19.
Heymann D, Rousselle AV: gp130 Cytokine family and bone cells. Cytokine. 2000, 12 (10): 1455-1468. 10.1006/cyto.2000.0747.CrossRefPubMed
20.
Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, et al: Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 120 (2): 582-592. 10.1172/JCI40568.
21.
Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C, Redini F, Heymann D, Blanchard F: Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res. 2004, 19 (11): 1850-1861. 10.1359/JBMR.040817.CrossRefPubMed
22.
Levy JB, Schindler C, Raz R, Levy DE, Baron R, Horowitz MC: Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells. Endocrinology. 1996, 137 (4): 1159-1165. 10.1210/en.137.4.1159.PubMed
23.
24.
Devarajan E, Huang S: STAT3 as a central regulator of tumor metastases. Curr Mol Med. 2009, 9 (5): 626-633. 10.2174/156652409788488720.CrossRefPubMed
25.
Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19 (21): 2474-2488. 10.1038/sj.onc.1203527.CrossRefPubMed
26.
Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, de Vos G, Hallek M: Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Mol Cell Biol. 2001, 21 (23): 8068-8081. 10.1128/MCB.21.23.8068-8081.2001.CrossRefPubMedPubMedCentral
27.
Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B: Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol. 1997, 25 (13): 1367-1377.PubMed
28.
Wang YC, Zheng LH, Ma BA, Zhou Y, Zhang MH, Zhang DZ, Fan QY: Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem. 2010
29.
Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H, Duan Z: Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res. 2010, 28 (7): 971-978.PubMed
30.
Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005, 65 (5): 1748-1754. 10.1158/0008-5472.CAN-04-2463.CrossRefPubMed
31.
Liao AT, McCleese J, Kamerling S, Christensen J, London CA: A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet Comp Oncol. 2007, 5 (3): 177-196. 10.1111/j.1476-5829.2007.00137.x.CrossRefPubMed
32.
Holm S: A simple sequentially rejective multiple test procedure. Scand J Statistics. 1979, 6: 65-70.
33.
Korzus E, Nagase H, Rydell R, Travis J: The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem. 1997, 272 (2): 1188-1196. 10.1074/jbc.272.2.1188.CrossRefPubMed
34.
Li WQ, Dehnade F, Zafarullah M: Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol. 2001, 166 (5): 3491-3498.CrossRefPubMed
35.
Lana SE, Ogilvie GK, Hansen RA, Powers BE, Dernell WS, Withrow SJ: Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res. 2000, 61 (2): 111-114. 10.2460/ajvr.2000.61.111.CrossRefPubMed
36.
Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 2005, 127 (2): 151-156. 10.1016/j.jss.2004.12.016.CrossRefPubMed
37.
Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P: Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev. 2010, 29 (2): 243-248. 10.1007/s10555-010-9227-2.CrossRefPubMed
38.
Danese S, Mantovani A: Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene. 2010, 29 (23): 3313-3323. 10.1038/onc.2010.109.CrossRefPubMed
39.
Scotlandi K, Picci P, Kovar H: Targeted therapies in bone sarcomas. Curr Cancer Drug Targets. 2009, 9 (7): 843-853. 10.2174/156800909789760410.CrossRefPubMed
40.
O'Day K, Gorlick R: Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009, 9 (4): 511-523.CrossRefPubMed
41.
de Hooge AS, van de Loo FA, Bennink MB, de Jong DS, Arntz OJ, Lubberts E, Richards CD, vandDen Berg WB: Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. Am J Pathol. 2002, 160 (5): 1733-1743. 10.1016/S0002-9440(10)61120-0.CrossRefPubMedPubMedCentral
42.
Yanai N, Obinata M: Oncostatin m regulates mesenchymal cell differentiation and enhances hematopoietic supportive activity of bone marrow stromal cell lines. In Vitro Cell Dev Biol Anim. 2001, 37 (10): 698-704. 10.1290/1071-2690(2001)037<0698:OMRMCD>2.0.CO;2.CrossRefPubMed
43.
Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL: Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 2005, 65 (19): 8896-8904. 10.1158/0008-5472.CAN-05-1734.CrossRefPubMed
44.
Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, et al: Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol. 2007, 27 (7): 1587-1595. 10.1161/ATVBAHA.107.143081.CrossRefPubMed
45.
Lim CP, Phan TT, Lim IJ, Cao X: Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. J Invest Dermatol. 2009, 129 (4): 851-861. 10.1038/jid.2008.337.CrossRefPubMed
46.
Chen SH, Gillespie GY, Benveniste EN: Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia. 2006, 53 (2): 191-200. 10.1002/glia.20264.CrossRefPubMed
47.
Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, Radka SF, Linsley PS: Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science. 1992, 255 (5050): 1432-1434. 10.1126/science.1542793.CrossRefPubMed
48.
Faffe DS, Flynt L, Mellema M, Whitehead TR, Bourgeois K, Panettieri RA, Silverman ES, Shore SA: Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta. Am J Physiol Lung Cell Mol Physiol. 2005, 288 (6): L1040-1048. 10.1152/ajplung.00333.2004.CrossRefPubMed
49.
Ehashi T, Koyama T, Ookawa K, Ohshima N, Miyoshi H: Effects of oncostatin M on secretion of vascular endothelial growth factor and reconstruction of liver-like structure by fetal liver cells in monolayer and three-dimensional cultures. J Biomed Mater Res A. 2007, 82 (1): 73-79.CrossRefPubMed
50.
Weiss TW, Speidl WS, Kaun C, Rega G, Springer C, Macfelda K, Losert UM, Grant SL, Marro ML, Rhodes AD, et al: Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res. 2003, 59 (3): 628-638. 10.1016/S0008-6363(03)00463-2.CrossRefPubMed
51.
Repovic P, Fears CY, Gladson CL, Benveniste EN: Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene. 2003, 22 (50): 8117-8124. 10.1038/sj.onc.1206922.CrossRefPubMed
52.
Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000, 6 (2): 572-577.PubMed
53.
Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y, Tsuneyoshi M: CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006, 19 (5): 738-745. 10.1038/modpathol.3800587.CrossRefPubMed
54.
Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, Zhao H, Yao Y: Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 2010
55.
Thamm DH, O'Brien MG, Vail DM: Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. Vet Comp Oncol. 2008, 6 (2): 126-132. 10.1111/j.1476-5829.2007.00153.x.CrossRefPubMed
56.
Wergin MC, Kaser-Hotz B: Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo. 2004, 18 (1): 15-19.PubMed
Metadata
Title
Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines
Authors
Stacey L Fossey
Misty D Bear
William C Kisseberth
Michael Pennell
Cheryl A London
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-125

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Technical advance

High resolution melting analysis for a rapid identification of heterozygous and homozygous sequence changes in the MUTYH gene

Debate

Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening

Research article

An in vitro co-culture model of esophageal cells identifies ascorbic acid as a modulator of cell competition

Research article

Hakai reduces cell-substratum adhesion and increases epithelial cell invasion

Commentary

Improved blood tests for cancer screening: general or specific?

Research article

Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits